AnKuo Biopharma
岸阔医药
AnKuo Biopharma (岸阔医药) is a biotech company focused on developing drugs to address side effects of cancer treatment, specifically targeting common dermatological toxicities from widely used oncology drugs . FreeS Fund (峰瑞资本) first invested in the company's Series A round in September 2019 and continued to back it in a subsequent $20 million A+ round announced in April 2021 . As of early 2023, AnKuo remained active in fundraising, having completed at least one financing round during 2022 alongside other FreeS portfolio companies in the biotech sector .
elsewhere's corpus does not cover more recent developments beyond this 2022-2023 timeframe.
AI-generated — may contain errors, please verify.
Coverage
How to Invest in Biotech in 2023? | FreeS Research
Data-driven, cross-disciplinary, bearing fruit — the most certain direction amid uncertainty
Our Year: Working Together, Staying the Course | FreeS Fund 2021 Year in Review
Walk alongside more outstanding founders.
FreeS Family Funding News · April | OnKure Therapeutics, IceKredit, Duanyu Liangjin, and Jiuzhou Yunjian Secure Funding
New Column Launch
